TPST
Tempest Therapeutics, Inc. Common Stock
stockNASDAQ
tempest therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. the molecules were developed by inception sciences, a versant ventures affiliated drug discovery engine. tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. tempest is backed by a syndicate of leading us and china based venture capital firms.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.83 | 2026-09-28 | -3.73% | 0.065 |
| 1M | 1.03 | 2026-09-04 | -22.27% | -8.441 |
| 3M | 1.07 | 2026-07-06 | -25.18% | -1.950 |
| 6M | 1.59 | 2026-04-06 | -49.65% | -0.301 |
| 1Y | 10.40 | 2025-10-03 | -92.30% | 0.630 |
| 2Y | 18.46 | 2024-10-04 | -95.66% | — |
| 5Y | 185.64 | 2021-10-04 | -99.57% | 2.467 |
Tempest Therapeutics, Inc. Common Stock (NASDAQ:TPST) stock price today is $0.80, and today's volume is 2,273,801. TPST is down 0.682% today. The 30 day average volume is 5.23M. TPST market cap is $13.52M with 16.89M shares outstanding.